Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

IRVINE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a propensity-matched comparison of patients treated in the CLOUT registry versus patients treated with pharmacomechanical thrombolysis in ATTRACT, an NIH-sponsored randomized controlled trial. Both data sets were presented during a late breaking clinical trial session at the VEINS conference in Las Vegas, NV.

Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline

IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Third Quarter 2022 Financial Results

Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.

Inari Medical (NARI) Posts Positive Results of FLASH Registry

Shares are down 25% year to date. Covid limited Inari's ability to develop the DVT market, so a post-pandemic constructive hospital environment provides them a nice tailwind going forward.

Inari Medical: Growth Set To Reaccelerate In The Back Half Of The Year

IRVINE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will host the Company's first Analyst and Investor Day on Thursday, September 15, 2022 at its headquarters in Irvine, CA.

Inari Medical to Host First Analyst & Investor Day

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock?

Inari Medical, Inc. (NARI) Down 16.4% Since Last Earnings Report: Can It Rebound?

IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the DEFIANCE trial.

Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023

Inari Medical, Inc. (NASDAQ:NARI ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Caroline Corner - IR Bill Hoffman - President and CEO Mitch Hill - CFO Drew Hykes - COO Tom Tu - CMO Conference Call Participants Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Marie Thibault - BTIG William Plovanic - Canaccord Genuity Adam Maeder - Piper Operator Good day, and thank you for standing by. Welcome to the Inari Medical Inc. Second Quarter Earnings Conference Call.

Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q2 2022 Results - Earnings Call Transcript

Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023 Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023

Inari Medical Announces Leadership Succession Plan

Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?

Inari Medical has curled up since May, with the share catching a bid and strengthening against key benchmarks. It has exposure to key alternative premia currently driving equity markets in FY22.

Inari Medical: Fundamentals Soft, Technicals Supportive Of Near-Term Upside Capture

IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Inari will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Second Quarter 2022 Financial Results

Matterport

These beaten-down stocks are poised to deliver enormous gains for patient investors.

Have $500 to Spare? Buy These 2 Top Stocks Now for 10X Gains

ALISO VIEJO, Calif. , June 7, 2022 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company's LOBO® Vascular Occlusion System.

OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDERS TO ADDRESS A WIDE RANGE OF PERIPHERAL EMBOLIZATION CASES

IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the publication of its first ever “Ethos and Sustainability Report.” The report highlights Inari's commitment to its ethos, and as part of that to environmental, social and governance (ESG) leadership. The report can be found on Inari's website here.

Inari Medical Announces Launch of 2021 Ethos and Sustainability Report

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

Inari Medical, Inc. (NASDAQ:NARI ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Caroline Corner - IR Bill Hoffman - CEO Mitch Hill - CFO Drew Hykes - COO Tom Tu - CMO Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Priya Sachdeva - SVB Leerink Operator Good day, and thank you for standing by. Welcome to the Inari Medical First Quarter 2022 Earnings Call.

Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q1 2022 Results - Earnings Call Transcript

Inari Medical Inc's (NASDAQ: NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million. The increase over the prior year was driven by continued U.S. commercial expansion and new product introductions.

Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus

IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022.

Inari Medical Reports First Quarter 2022 Financial Results

Inari Medical, Inc. (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Inari Medical, Inc. (NARI): Can Its 6.2% Jump Turn into More Strength?

IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the Bank of America 2022 Healthcare Conference on Thursday, May 12, 2022 at 10:40 a.m. Pacific Time at the Encore Hotel in Las Vegas.

Inari Medical to Present at the Bank of America 2022 Healthcare Conference

IRVINE, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

News for Inari Medical Stock (NARI)